David James Harrison

This study elucidates the mechanism of YRDC catalysis, showing that threonine stabilizes the enzyme and dimerization is critical for function, with disease-linked mutations disrupting these processes.

The paper designs improved nucleoside 2'-deoxyribosyltransferase enzymes with enhanced catalytic efficiency and broad substrate promiscuity for generating diverse nucleoside products.

NUC-3373, a phosphoramidate-modified FUDR, induces DNA damage and DAMPs release in CRC cells, enhancing lymphocyte-mediated cell death and synergizing with PD-1 inhibitors.

This study examines clonal dynamics and somatic evolution in mouse haematopoiesis, finding that stem cells accrue mutations at a rate similar to human progenitors and exhibit distinct age-related patterns.

The paper uses long-read spatial transcriptomics on ccRCC tumoroids to reveal gene and isoform expression heterogeneity, identifying distinct functional tumor clusters and isoform-specific patterns.

The paper evaluates a workflow for spatially co-registering molecular and phenotypical data from human kidney tissue using DESI-MSI under varying conditions.

The paper identifies key predictors of PD-1 blockade response in renal cell carcinoma by analyzing the tumor microenvironment of metastatic sites and developing a predictive TID score.

The paper develops COD-dipp to map MHC Class I antigens from cancer studies and identifies immune-relevant genomic regions for vaccine design.